FDA approves Gilotrif for the treatment of a type of late-stage lung cancer
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved GILOTRIF (afatinib) tablets for oral use, as a new first-line (initial) treatment for patients More...